Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.40 |
| ▸ | ACE | P12821 | 8/20 | 0.39 |
| ▸ | REN | P00797 | 3/20 | 0.37 |
| ▸ | LTA4H | P09960 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PEPD | P12955 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL678487 | 1.00 | DPP4 (0.42) | DPP4DPP8DPP9ACEREN | |
| SCHEMBL4595209 | 0.93 | DPP4 (0.44) | DPP4DPP8DPP9ACEREN | |
| SCHEMBL4595206 | 0.93 | DPP4 (0.44) | DPP4DPP8DPP9ACEREN | |
| SCHEMBL5734357 | 0.93 | DPP4 (0.44) | DPP4DPP8DPP9ACEREN | |
| SCHEMBL7759091 | 0.89 | DPP4 (0.42) | DPP4DPP8DPP9ACEREN | |
| SCHEMBL10454953 | 0.89 | TRHR (0.43) | DPP4DPP8DPP9ACEREN | |
| SCHEMBL7759104 | 0.89 | DPP4 (0.42) | DPP4DPP8DPP9ACEREN | |
| SCHEMBL10454951 | 0.89 | TRHR (0.43) | DPP4DPP8DPP9ACEREN | |
| SCHEMBL2560552 | 0.85 | DPP4 (0.39) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL29591738 | 0.84 | TRHR (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002001956-A1 | HISTIDYL-PROLINE DIKETOPIPERAZINE AND METHOD OF USE | PRASAD CHANDAN (US) | 2002-01-10 | — | — | WO | claimed |
| US-6090780-A | ADMINISTERING TO THE PATIENT SUFFERING FROM ALCOHOL ADDITION HISTIDYL-PROLINE DIKETOPIPERZINE OR STERIOISOMER TO ATTENUATE THE DESIRE OF ALCOHOL WITHOUT SUPPRESSING THE APPETITE | CHANDON PRASAD (US) | 2000-07-18 | — | — | US | claimed |
| US-5418218-A | Histidyl-proline diketopiperazine (cyclo his-pro) a cns-active pharmacologic agent | THE UNIVERSITY OF MARYLAND AT BALTIMORE (US) | 1995-05-23 | — | — | US | claimed |
| US-4426378-A | Thyrotropin releasing hormone in therapy of shock and as a central nervous system stimulant | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1984-01-17 | — | — | US | claimed |
| US-8849577-B2 | Methods of identifying biochemical pathways | METABOLON, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| WO-2012170599-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| EP-2382975-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2377530-A2 | Modulation of neurogenesis by PDE inhibition | Braincells, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-2377531-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-7998971-B2 | 2-(2-oxopyrrolidin- 1 -yl)-N-(2,3 -dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)acetoamide (MKC-231) and a second active ingredient for treating central or peripheral nervous system disorders increase neurogenesis; synergistic; drug addiction, psychological disorders, transplant rejection | BRAINCELLS INC. (US) | 2011-08-16 | — | — | US | disclosed |
| WO-2000020024-A2 | METHODS FOR THE TREATMENT OF NON-THYROID DISORDERS | CELTRIX PHARMACEUTICALS, INC. (US) | 2000-04-13 | — | — | WO | disclosed |
| US-5418218-A | Histidyl-proline diketopiperazine (cyclo his-pro) a cns-active pharmacologic agent | THE UNIVERSITY OF MARYLAND AT BALTIMORE (US) | 1995-05-23 | — | — | US | disclosed |
| US-5418218-A | Histidyl-proline diketopiperazine (cyclo his-pro) a cns-active pharmacologic agent | THE UNIVERSITY OF MARYLAND AT BALTIMORE (US) | 1995-05-23 | — | — | US | disclosed |
| EP-0422140-A1 | THYROLEBERIN AS IMMUNOMODULATOR AND LIPID REGULATOR | PIERPAOLI, Walter (CH) | 1991-04-17 | — | — | EP | disclosed |
| WO-1990008583-A2 | THYROLEBERIN AS IMMUNOMODULATOR AND LIPID REGULATOR | PIERPAOLI WALTER (CH) | 1990-08-09 | — | — | WO | disclosed |
| EP-0168401-A1 | IMMUNOGENIC COMPOSITIONS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1986-01-22 | — | — | EP | disclosed |
| WO-1984003629-A1 | IMMUNOGENIC COMPOSITIONS | CRIGHTON DAVID BARRY | 1984-09-27 | — | — | WO | disclosed |
| US-4426378-A | Thyrotropin releasing hormone in therapy of shock and as a central nervous system stimulant | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1984-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | DPP4 1663/4885DPP8 1082/4885DPP9 1323/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | DPP4 151/4885DPP8 416/4885DPP9 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.